21.65MMarket Cap-221P/E (TTM)
0.880High0.830Low293.90KVolume0.860Open0.875Pre Close248.24KTurnover2.33%Turnover RatioLossP/E (Static)25.77MShares12.88052wk High-0.39P/B10.59MFloat Cap0.78052wk Low--Dividend TTM12.61MShs Float12.880Historical High--Div YieldTTM5.71%Amplitude0.780Historical Low0.844Avg Price1Lot Size
NKGEN BIOTECH Stock Forum
A 90% improved cognitive function for Alzheimer’s disease is a very impressive outcome for this trial.
NKGen Biotech Presents New Positive SNK01 Biomarker Data at the 2024 Alzheimer’s Association International Conference
NKGen Biotech presented new positive data on its SNK01 therapy for Alzheimer's disease at the 2024 AAIC.
The study showed that SNK01, a cryopreserved autologous non-genetically modified NK cell product, can effectively reduce α-synuclein (α-syn) protein levels in the cerebrospinal fluid of Alzheimer's patients. This is significant as increased α-syn ...
📊⚡️📊
No comment yet